OBJECTIVE To study the influence of n-3 polyunsaturated fatty acids (n-3-PUFAs) on liver lipidomics in type 2 diabetic rats, and to investigate the possible molecular mechanism. METHODS Type 2 diabetes rats were induced by high-fat and high-sugar diet followed with streptozotocin injection. All rats were randomly divided into four groups：the control group, the model group, the n-3-PUFAs group and gliquidone（Glurenor） group. The animals were sacrificed after the 12 weeks of administration. The fasting blood glucose, the weight of liver, the index of liver, TG and TC contents in liver and serum were measured. The level of SREBP-1 in liver was measured by Western blot. SREBP-1 mRNA, FAS mRNA and ACC mRNA expressions were measured with RT-PCR. RESULTS The rats in n-3-PUFAs group showed characters of obesity. The TG in serum of the n-3-PUFAs group was lower than that in the model group (P＜0.01). The TG contents in liver, the weight of liver and the index of liver were higher than those of model group(P＜0.01). The expression levels of SREBP-1c, FAS and ACC mRNA in the n-3-PUFAs group were higher than those in the model group(P＜0.01). CONCLUSION Although n-3-PUFAs reduces the level of serum TG, it causes obesity and liver lipidomics, and it can′t suppress the overexpression of SREBP-1c, FAS and ACC in the liver of type 2 diabetic rats.
Key words
n-3 polyunsaturated fatty acids /
type 2 diabetic /
lipid deposit /
sterol regulatory element-binding protein 1c
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
［1］ MCPHERSON R, GAUTHIER A. Molecular regulation of SREBP function：the Insig-SCAP connection and isoform-specific modulation of lipid synthesis［J］. Biochem Cell Biol，2004, 82 (1)：201-211.
［2］ FORETZ M, GUICHARD P, FERRE P, et al. SREBP-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes［J］. Proc Natl Acad Sci USA, 1999, 96(22)：12737-12742.
［3］ EDWARDS P A, TABOR D, KAST H R, et al. Regulation of gene expression by SREBP and SCAP［J］. Biochim Biophys Acta，2000, 1529(1-3)：103-113.
［4］ GUO X H，LIU Z H，LI H, et al. Type 2 diabetes mellitus induced by diets and its features of renal involvement in rat［J］. Chin J Diabet（中国糖尿病杂志），2002，10（5）：290-294.
［5］ DANDA R S, HABIBA N M, RINCON C H, et al. Kidney involvement in a nongenetic rat model of type 2 diabetes［J］. Kidney Int，2005，68(6)：2562-2571.
［6］ CHINESE SOCIETY OF HEPATOLOGY OF NONALCOHOLIC AND ALCOHOLIC FATTY LIVER GROUP. Diagnostic standard of nonalcoholic fatty liver［J］. Chin J Hepatol（中华肝脏病杂志）, 2001, 9(6)：325.
［7］ CLORE J N, STILLMAN J S, JING L, et al. Differential effect of saturated and polyunsaturated fatty acids on hepatic glucose metabolismin humans［J］. Am J Physiol Endocrinol Metab, 2004, 287(2)：358-365.
［8］ FLACHS P, ROSSMEISL M, BRYHN M, et al. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism［J］.Clin Sci (Lond), 2009, 116(1)：1-16.
［9］ SEKIYA M, YAHAGI N, MATSUZAKA T, et al.Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression［J］. Hepatology，2003, 38(6)：1529-1539.
［10］ CAPANNI M, CALELLA F, BINGINI M R, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease：a Pilot study［J］. Aliment Pharmacol Ther, 2006, 23(8)：1143-1151.
［11］ PEYRON C E, TAVERNA M, MICHELE G M, et al. Dietary (n-3) polyunsaturated fattyacids up-regulate plasma leptin in insulin-resistant rats［J］. J Nutr，2002, 132(8)：2235-2240.
［12］ CHEN Y J，ZHOU G H，XU X L. Disease preventing and curing function of n-3 polyunsaturated fatty acids［J］. China Oils Fats（中国油脂），2006，31（9）：31-34.
［13］ MONTELL E, TURINI M, MAROTTA M, et al. DAG Accumulation from saturated fatty acidsdesensitizes insulin stimulation of glucose uptake in muscle cells［J］. Am J Physiol Endocrinol Metab, 2001, 280（2）：229-237.
［14］ HAN P，LU Y，XIA F, et al. Effect of polyunsaturated fatty acids on hepatic triglyceride content and insulin resistance［J］. Chin J Diabet（中国糖尿病杂志）， 2007，15（7）：405-407.
［15］ IRVING G F, FREUND L Y, ERIKSDOTTER J M. Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer′s disease：the Omega-3 Alzheimer′s disease study［J］. J Am Geriatr Soc，2009, 57(1)：11-17.
［16］ SONG X Y, CHEN Q, QI X Y. Effect of Liuwei Dihuang pill on erythrocyte aldose reductase activity in early diabetic nephropathy patients［J］. Chin J Integr Med（中国中西医结合杂志), 2004，24(12)：1087-1090.
［17］ NITIYANANT W, SRIUSSADAPORN S, DEEROCHANAWONG C, et al. The efficacy and safety of gliquidone in Thai diabetics［J］. J Med Assoc Thai，1997, 80(12)：771-777.
［18］ LIU G L, ZHAO X J, DU J, et al. Clinical observation on the efficacy of glurenorm in the treatment of type 2 diabetes［J］. Liaoning J Pract Diabetol，2004, 12(3)：58-60.
{{custom_fnGroup.title_en}}
Footnotes
{{custom_fn.content}}
PDF(1397 KB)
